Latest beta-2 Stories
LONDON, June 3, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
REDWOOD CITY, Calif., June 16, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. today announced the advancement of its dual combination product candidate, PT003 and its individual components, PT001 and PT005 into a series of planned Phase 2 studies in patients with moderate-to-severe COPD.
REDWOOD CITY, Calif., May 18, 2011 /PRNewswire/ -- Pearl Therapeutics Inc.
CRANBURY, N.J., March 3, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced that the U.S.
Researchers at the University of Illinois have identified a potential drug target for the treatment of Alzheimerâ€™s disease: a receptor that is embedded in the membrane of neurons and other cells.
Researchers at the Stanford University School of Medicine have taken an early step toward identifying a new approach to drug discovery that may eventually yield drugs with fewer side effects.
NEW YORK, Dec.
- Growing in low tufty patches.